{"owner": "ArrayExpress Uploader", "pop_total": 0, "species": "human", "factors": [{"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945910": {"DISEASE STATE": "acute hepatitis"}}, {"GSM945916": {"DISEASE STATE": "healthy"}}, {"GSM945916": {"DISEASE STATE": "healthy"}}], "id": 4504, "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic response (SVR) to treatment with pegylated...", "geo_gse_id": "E-GEOD-38597", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 8, "tags": ["ahc", "chronic hepatitis", "chronic hepatitis c", "liver", "protein", "virus infection"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "gene-expression-profiling-of-6-acute-hepatitis-c-p", "geo_id_plat": "E-GEOD-38597_A-AFFY-44", "name": "Gene expression profiling of 6 acute hepatitis C patients", "created": "Sep.19, 2014", "summary": "Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic response (SVR) to treatment with pegylated interferon (pegINF)-\u03b1 and ribavirin. Non-response to treatment is associated with constitutively increased expression of IFN-stimulated genes (ISGs) in the liver. Treatment of patients with acute hepatitis C (AHC) is more effective, with SVR rates >90%. We investigated mechanisms of the different responses of patients with CHC and AHC to pegIFN-\u03b1 therapy. We analyzed IFN signaling and ISG expression in liver samples from patients with acute hepatitis C (AHC), patients with chronic hepatitis (CHC), and individuals without hepatitis C (controls) using microarray, immunohistochemical, and protein analyses. Findings were compared with those from primary human hepatocytes stimulated with IFN-\u03b1 or IFN-\u03b3, as reference sets. Expression levels of 100s of genes, primarily those regulated by IFN-\u03b3, were altered in liver samples from patients with AHC compared with controls. Expression of IFN-\u03b3\u2013stimulated genes was induced in liver samples from patients with AHC, whereas expression of IFN-\u03b1\u2013stimulated genes was induced in samples from patients with CHC. In an expression analysis of negative regulators of IFN-\u03b1 signaling, we did not observe differences in expression of SOCS1 or SOCS3 between liver samples from patients with AHC and those with CHC. However, USP18 (another negative regulator of IFN-\u03b1 signaling), was upregulated in liver samples of patients with CHC that did not respond to therapy, but not in AHC. In conclusion, differences in expression of ISGs might account for the greater response of patients with AHC, compared to those with CHC, to treatment with pegINF-\u03b1 and ribavirin. Specifically, USP18 is upregulated in liver samples of patients with CHC that do not respond to therapy, but not in patients with AHC.  (Interferon-\u03b3 Stimulated Genes, but not USP18, are Expressed in Livers of Patients with Acute Hepatitis C; Dill MT, Makowska Z et al, Gastroenterology 2012 (in press)) Liver biopsy samples from 6 patients with acute hepatitis C virus infection were analyzed CHC data and controls previously submitted as GSE11190", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-38597", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-38597/samples/"}